

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/536,860-Conf. #4611
				Filing Date	January 6, 2006
				First Named Inventor	Hana Golding
				Art Unit	1648
				Examiner Name	S. B. Chen
				Attorney Docket Number	65831(47992)
<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
					T <sup>6</sup>
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	C1	von Krempelhuber et al., "A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate." Vaccine. 2010 Feb 3;28(5):1209-16. Epub 2009 Nov 25			
	C2	Meseda et al., "Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model," Clin Vaccine Immunol. 2009 Sep;16(9):1261-71. Epub 2009 Jul 15			
	C3	Kennedy et al., "Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay," Clin Vaccine Immunol. 2009 Aug;16(8):1105-12. Epub 2009 Jun 17			
	C4	Garber et al., "Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies," PLoS One. 2009;4(5):e5445. Epub 2009 May 6			
	C5	Kennedy et al., "Gender effects on humoral immune responses to smallpox vaccine," Vaccine. 2009 May 26;27(25-26):3319-23			
	C6	Haralambieva et al., "Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles virus immunity," Clin Vaccine Immunol. 2008 Jul;15(7):1054-9			
	C7	Kaufman et al., "Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice," J Virol. 2008 Jul;82(14):6829-37			
	C8	Lustig et al., "Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge," J Virol. 2005 Nov;79(21):13454-62			
	C9	Snyder et al., "Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol. 2004 Jul;78(13):7052-60			
	C10	Cosma et al., "Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus," Clin Diagn Lab Immunol. 2004 Mar;11(2):406-10			
Examiner Signature	/Stacy B. Chen/	Date Considered	04/14/2011		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: March 11, 2011

Electronic Signature for Gabriel J. McCool: /Gabriel J. McCool/